促红细胞生成素及铁剂治疗肾性贫血的合理性评价

Evaluation of the application rationality of erythropoietin and iron treatment for renal anemia

目的评价肾性贫血药物治疗方案的合理性,建立肾性贫血药物使用的临床路径,规范肾性贫血药物治疗。方法依据国内外相关指南、共识、参考文献及药品说明书建立肾性贫血药物治疗评价标准,回顾性分析肾性贫血患者的药物治疗方案(促红细胞生成素、蔗糖铁复合物和多糖铁复合物),对其合理性进行评价。结果 511例肾性贫血患者中,促红细胞生成素使用合理率为80.63%,铁剂使用合理率为48.14%,血红蛋白值与促红细胞生成素用药合理性相关(P<0.05),年龄、铁蛋白值、疾病数、是否联用促红细胞生成素与铁剂用药合理性相关(P<0.05)。结论建立的肾性贫血药物治疗方案合理、标准明确、简单易行,为肾性贫血规范化治疗提供参考。

Objective To evaluate the rationality of treatment proposal about renal anemia,and to establish the clinical pathways of renal anemia.Methods Based on the domestic and foreign relevant guidelines,consensus,reference and drug instructions,the evalutation standard of drug treatment about renal anemia was established,and retrospectively analyzed,with regard to renal anemia drugs（erythropoietin and iron sucrose complex,polysaccharide-iron complex）during the 2014 of Northwest Third Grade Class Hosptial,Results Among 511 cases of patients with renal anemia,iron using reasonable rate was 48.14%,erythropoietin using reasonable rate was 80.63%.Age,ferritin values,number of disease,combined with erythropoietin（EPO）were related to the rationality of iron（P〈0.05）,and hemoglobin values were related to the rationality of erythropoietic（P〈0.05）.Conclusion The proposal standard is clear and simple,which provides a reference for the standardized treatment of renal anemia.